Syringa Vulgaris Flower

Dosage for Syringa Vulgaris Flower extract is highly individualized and must be determined by an allergist based on the patient's sensitivity. There is no 'standard' dose for all patients.

Skin Testing Dosage

• Prick/Scratch Testing: Usually, a single drop of the 1:20 w/v concentration is applied to the skin.
• Intradermal Testing: If the prick test is negative, 0.02 mL to 0.05 mL of a 1:1000 w/v or 1:500 w/v dilution may be injected into the dermis.

Immunotherapy (Allergy Shots)

• Build-up Phase: Treatment usually begins with a very low dose (e.g., 0.05 mL of a 1:100,000 w/v dilution). Injections are typically given 1 to 2 times per week, with the dose increasing by 20% to 50% at each visit, provided no significant local or systemic reactions occur.
• Maintenance Phase: Once the 'top dose' or maximum tolerated dose is reached (often 0.5 mL of a 1:20 w/v or 1:100 w/v concentration), the interval between injections is increased to every 2 to 4 weeks.

Syringa Vulgaris Flower extract is generally considered safe for use in children, provided they are old enough to cooperate with the testing and injection procedure.

• Dosing: Pediatric dosing follows the same weight/volume titration principles as adult dosing. However, smaller initial volumes may be used to minimize discomfort.
• Safety: Children should be monitored even more closely for signs of systemic reactions, as they may not be able to articulate early symptoms of anaphylaxis as clearly as adults.

Renal Impairment

No specific dosage adjustments are required for patients with renal impairment, as the systemic load of the protein extract is minimal.

Hepatic Impairment

No dosage adjustments are necessary for hepatic impairment.

Elderly Patients

Elderly patients may have a reduced skin response to testing. Caution is advised if the patient has underlying cardiovascular disease, as they may be less able to tolerate the physiological stress of a systemic reaction or the administration of epinephrine.

Syringa Vulgaris Flower extract is for professional use only and is never self-administered by the patient at home.

• Administration: Injections are given subcutaneously (under the skin), usually in the posterior aspect of the upper arm. The injection should never be given intravenously.
• Observation: Patients must remain in the medical office for at least 30 minutes after every injection to monitor for signs of a systemic reaction or anaphylaxis.
• Storage: Vials must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Freezing will denature the proteins and render the extract ineffective.

If a dose in the build-up phase is missed, the next dose may need to be reduced or maintained at the previous level depending on the length of the delay.

• Delay of 1 week: Usually, the dose can be maintained.
• Delay of 2-4 weeks: The dose is often reduced by one or two levels to ensure safety.
• Longer delays: The build-up may need to be restarted from a much lower concentration.

An 'overdose' in the context of allergenic extracts refers to receiving a dose higher than the patient's current tolerance level. This can lead to severe systemic reactions.

• Signs: Rapid onset of hives, swelling of the throat, wheezing, or a drop in blood pressure.
• Emergency Measures: Administration of epinephrine (1:1000) via intramuscular injection is the primary treatment. Oxygen, IV fluids, and antihistamines may also be required.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or skip appointments without medical guidance, as this increases the risk of a reaction.

Most patients receiving Syringa Vulgaris Flower extract will experience some form of local reaction. These are generally considered part of the body's normal response to the allergen.

• Local Redness (Erythema): A red patch at the injection site that may appear within minutes and last for several hours.
• Local Swelling (Wheal): A raised, itchy bump at the injection site. If the swelling is smaller than the size of a half-dollar (approx. 3 cm), it is usually considered a normal local reaction.
• Pruritus (Itching): Intense itching at the site of the skin test or injection.

• Large Local Reactions: Swelling that exceeds 5-10 cm in diameter. This may indicate that the next dose should be reduced or held constant.
• Fatigue: Some patients report feeling unusually tired for a few hours following an immunotherapy injection.
• Mild Nasal Congestion: A slight increase in hay fever symptoms shortly after treatment.

• Generalized Urticaria (Hives): Itchy welts appearing on parts of the body away from the injection site.
• Angioedema: Swelling of the deeper layers of the skin, often around the eyes or lips.
• Persistent Lymphadenopathy: Swelling of the lymph nodes near the injection site.

> Warning: Stop taking Syringa Vulgaris Flower and call your doctor immediately if you experience any of these symptoms of a systemic reaction.

• Anaphylaxis: A life-threatening, multi-system allergic reaction. Symptoms include a rapid pulse, difficulty breathing, and a sudden drop in blood pressure.
• Bronchospasm: Tightness in the chest, wheezing, or significant shortness of breath.
• Laryngeal Edema: A feeling of 'tightness' in the throat, difficulty swallowing, or a hoarse voice, indicating airway swelling.
• Hypotension (Shock): Feeling faint, dizzy, or losing consciousness.
• Severe Abdominal Cramping: Sometimes accompanied by nausea or vomiting, which can be a sign of a systemic allergic response.

There are no known long-term toxicities associated with the use of Syringa Vulgaris Flower extract. Because it is a biological protein, it does not accumulate in the tissues like some synthetic drugs. The primary long-term risk is the development of new sensitivities, although this is rare. Most patients find that after 3 to 5 years of successful immunotherapy, their sensitivity to lilac pollen is significantly and permanently reduced.

Allergenic extracts, including Syringa Vulgaris Flower, carry a class-wide FDA warning regarding the risk of severe systemic reactions.

• Anaphylaxis Risk: This product can cause severe life-threatening systemic reactions, including anaphylaxis.
• Supervision: It must only be administered by healthcare providers prepared to manage such reactions.
• Observation: Patients must be observed for at least 30 minutes in the office after administration.
• Pre-existing Conditions: Patients with unstable asthma are at a higher risk for severe reactions and should be evaluated carefully before each injection.

Report any unusual symptoms or delayed reactions (occurring hours after the injection) to your healthcare provider immediately.

Syringa Vulgaris Flower extract is a potent biological agent. Its use requires strict adherence to safety protocols to prevent life-threatening allergic reactions. Patients must be communicative with their providers regarding how they felt after their last dose.

No FDA black box warnings are specific solely to Syringa Vulgaris Flower, but it is covered under the general boxed warning for all Allergenic Extracts. The warning emphasizes that these products can cause severe anaphylaxis and should only be administered in settings where emergency resuscitation equipment and trained personnel are immediately available.

• Allergic Reactions / Anaphylaxis Risk: This is the primary concern. Any history of a previous severe reaction to lilac or other Oleaceae pollens (like Ash or Privet) must be disclosed.
• Asthma Status: Patients with severe or poorly controlled asthma (FEV1 < 70% of predicted) are at a significantly higher risk for a fatal reaction if they experience anaphylaxis. Immunotherapy should be deferred if the patient is experiencing an asthma flare-up.
• Cardiovascular Disease: Patients with significant heart disease may not tolerate the physiological stress of a reaction or the side effects of epinephrine (the primary treatment for anaphylaxis).
• Beta-Blocker Use: Patients taking beta-blockers may be resistant to the effects of epinephrine, making anaphylaxis much harder to treat.

• Baseline Testing: Before starting treatment, a thorough history and physical exam are required.
• Lung Function: For asthmatic patients, a peak flow or spirometry test may be performed before each injection.
• Injection Site Check: The provider will check for large local reactions from the previous visit before administering a new dose.
• Wait Time: A mandatory 30-minute post-injection wait time is strictly enforced in all clinical settings.

Most patients can drive after the 30-minute observation period. However, if you feel dizzy, fatigued, or experience any systemic symptoms, do not operate heavy machinery and notify your doctor.

While there is no direct chemical interaction between alcohol and Syringa Vulgaris Flower extract, alcohol consumption can increase peripheral vasodilation. This might theoretically speed up the absorption of the allergen or mask the early symptoms of an allergic reaction. It is generally advised to avoid heavy alcohol use on the day of an injection.

If you decide to stop immunotherapy, there are no withdrawal symptoms. However, your allergy symptoms will likely return to their baseline levels over time. If treatment is paused for more than a few weeks, it cannot be resumed at the same dose; a 'step-back' in dosage is required for safety.

> Important: Discuss all your medical conditions, especially respiratory or heart issues, with your healthcare provider before starting Syringa Vulgaris Flower.

There are no absolute drug-drug contraindications that prevent the use of Syringa Vulgaris Flower extract, but certain combinations make the treatment significantly more dangerous.

• Beta-Adrenergic Blockers (Beta-Blockers): While not strictly contraindicated in all cases, they are often avoided. Beta-blockers can increase the severity of anaphylaxis and, more importantly, can block the life-saving effects of epinephrine if an emergency occurs.

• ACE Inhibitors: Some studies suggest that patients on ACE inhibitors may have more frequent or more severe systemic reactions to allergenic extracts.
• MAO Inhibitors: These can potentiate the effect of epinephrine, which could lead to a hypertensive crisis if epinephrine is needed to treat a reaction to the extract.
• Tricyclic Antidepressants: Similar to MAOIs, these can increase the cardiovascular risks associated with emergency epinephrine administration.

• Antihistamines (H1 Blockers): Drugs like loratadine, cetirizine, and diphenhydramine will suppress the skin's reaction to the extract. This leads to false-negative results during diagnostic testing. These should be stopped 3 to 7 days before skin testing.
• H2 Blockers: Drugs like famotidine can also slightly decrease skin test reactivity and should be discontinued prior to diagnostic procedures.
• Systemic Corticosteroids: High doses of oral steroids may suppress the immune response, potentially making skin testing less accurate or requiring a pause in immunotherapy.

There are no known direct food interactions with Syringa Vulgaris Flower extract. However, patients with a 'pollen-food allergy syndrome' (Oral Allergy Syndrome) may find that eating certain raw fruits or vegetables during lilac season increases their overall 'allergic load,' potentially making them more sensitive to their injections.

• St. John's Wort: May theoretically interact with medications used to treat anaphylaxis.
• Feverfew/Ginkgo: These may have mild anti-platelet effects but generally do not interfere with the extract itself.

Syringa Vulgaris Flower extract does not typically interfere with standard blood chemistry or hematology tests. However, it will directly affect:

• Skin Prick Tests: As intended, it causes a wheal and flare.
• In Vitro IgE Testing (sIgE): Recent immunotherapy can cause a transient rise in specific IgE levels before they eventually decline.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially any heart or blood pressure medications.

Syringa Vulgaris Flower extract must NEVER be used in the following circumstances:

1. 1Severe, Uncontrolled Asthma: If a patient's asthma is not stable, the risk of a fatal bronchospasm during a systemic reaction is unacceptably high.
2. 2Recent Myocardial Infarction (Heart Attack): Within the last 3-6 months, as the heart may not be able to tolerate the stress of a reaction or epinephrine.
3. 3Previous Near-Fatal Reaction: If a patient has had a prior life-threatening reaction to Syringa Vulgaris Flower or closely related extracts.
4. 4Hypersensitivity to Diluents: Some extracts contain phenol or glycerin as preservatives; patients with a known allergy to these components cannot use the extract.

These conditions require a careful risk-benefit analysis by the physician:

• Autoimmune Diseases: There is a theoretical risk that immunotherapy could exacerbate certain autoimmune conditions, though clinical evidence is limited.
• Malignancy: Patients undergoing active chemotherapy or with unstable cancer are generally not started on immunotherapy.
• Beta-Blocker Therapy: As noted, this complicates the treatment of anaphylaxis.

Syringa Vulgaris is part of the Oleaceae family. Patients who are highly allergic to the following may show cross-reactivity with lilac extract:

• Ash Trees (Fraxinus)
• Privet (Ligustrum)
• Olive Trees (Olea)
• Forsythia

If you are allergic to one of these, your doctor may use a lower starting dose of Syringa Vulgaris Flower extract to ensure safety.

> Important: Your healthcare provider will evaluate your complete medical history and current health status before prescribing Syringa Vulgaris Flower.

• FDA Category: Not formally assigned, but generally handled with caution.
• Risk Summary: Immunotherapy is typically not started during pregnancy due to the risk of anaphylaxis, which can cause fetal hypoxia (lack of oxygen). However, if a patient is already on a stable maintenance dose and is tolerating it well, many allergists will continue the treatment at the same or a slightly reduced dose.
• Teratogenicity: There is no evidence that Syringa Vulgaris Flower extract causes birth defects.

• Passage into Milk: It is highly unlikely that the allergenic proteins in the extract pass into breast milk in any significant amount.
• Safety: Immunotherapy is generally considered safe for breastfeeding mothers. There are no known adverse effects on the nursing infant.

• Approved Age: There is no specific lower age limit, but it is rarely used in children under age 5 because they may find the frequent injections and the 30-minute wait difficult to tolerate.
• Growth Effects: There is no evidence that allergenic extracts affect growth or development.
• Benefits: Early immunotherapy in children may prevent the development of asthma later in life, a concept known as the 'Allergic March.'

• Risk Profile: Elderly patients are more likely to have co-morbidities like hypertension or coronary artery disease that increase the risk of immunotherapy.
• Pharmacokinetics: Age-related changes in the skin may result in smaller wheal-and-flare reactions during testing, potentially leading to under-diagnosis.

No dosage adjustments are required. The proteins are metabolized locally and systemically by proteases and do not rely on renal clearance for their primary immunological effect.

No dosage adjustments are required. The liver is not significantly involved in the processing of subcutaneous allergenic extracts.

> Important: Special populations require individualized medical assessment. Always inform your doctor if you are pregnant or planning to become pregnant while receiving allergy shots.

Syringa Vulgaris Flower extract acts as an exogenous antigen. In sensitized individuals, the primary molecular targets are the High-Affinity IgE Receptors (FcεRI) located on the surface of mast cells and basophils.

1. 1Sensitization Phase: Upon initial exposure, the immune system produces specific IgE antibodies against lilac pollen proteins.
2. 2Elicitation Phase (Testing): When the extract is introduced, it cross-links the IgE on mast cells, causing an influx of calcium ions and the release of pre-formed mediators (histamine).
3. 3Desensitization Phase (Therapy): Repeated low-dose exposure induces the expansion of Regulatory T-cells (Tregs), which secrete IL-10 and TGF-beta. This suppresses the allergic Th2 response and promotes the production of IgG4 blocking antibodies.

• Onset of Action: Skin test reactions occur within 15-20 minutes. For immunotherapy, clinical improvement in symptoms usually takes 3 to 6 months of consistent treatment.
• Duration of Effect: A single immunotherapy injection provides immunological modulation for weeks. After a full 3-5 year course, the effect can last for many years or even a lifetime.
• Tolerance: Unlike many drugs, 'tolerance' in this context is the goal—the body becomes 'tolerant' to the allergen.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Subcutaneous/Local) |

| Protein Binding | Minimal (Interacts with IgE/IgG) |

| Half-life | Hours (Proteins) to Weeks (Immune memory) |

| Tmax | 15-30 minutes (Local reaction) |

| Metabolism | Proteolytic degradation |

| Excretion | Renal (Degraded fragments) |

• Composition: A complex aqueous extract containing proteins (including the major allergen Syr v 1), glycoproteins, and minor carbohydrates.
• Molecular Weight: Ranges from 10 kDa to over 70 kDa for various protein fractions.
• Solubility: Highly soluble in buffered saline or glycerin-saline solutions.

Syringa Vulgaris Flower belongs to the Non-Standardized Pollen Allergenic Extract [EPC] class. It is grouped with other Oleaceae extracts like Ash and Privet due to their shared botanical and antigenic characteristics.